Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Retained Earnings (2019 - 2025)

Revolution Medicines has reported Retained Earnings over the past 7 years, most recently at -$2.9 billion for Q4 2025.

  • Quarterly results put Retained Earnings at -$2.9 billion for Q4 2025, down 65.1% from a year ago — trailing twelve months through Dec 2025 was -$2.9 billion (down 65.1% YoY), and the annual figure for FY2025 was -$2.9 billion, down 65.1%.
  • Retained Earnings for Q4 2025 was -$2.9 billion at Revolution Medicines, down from $3.1 million in the prior quarter.
  • Over the last five years, Retained Earnings for RVMD hit a ceiling of $3.1 million in Q3 2025 and a floor of -$2.9 billion in Q4 2025.
  • Median Retained Earnings over the past 5 years was -$2.1 million (2022), compared with a mean of -$585.5 million.
  • Biggest five-year swings in Retained Earnings: crashed 840991.67% in 2021 and later soared 100.2% in 2025.
  • Revolution Medicines' Retained Earnings stood at -$376000.0 in 2021, then plummeted by 186426.86% to -$701.3 million in 2022, then surged by 100.08% to $544000.0 in 2023, then tumbled by 319548.71% to -$1.7 billion in 2024, then tumbled by 65.1% to -$2.9 billion in 2025.
  • The last three reported values for Retained Earnings were -$2.9 billion (Q4 2025), $3.1 million (Q3 2025), and $1.3 million (Q2 2025) per Business Quant data.